This Cambridge company develops drugs using fragments of molecules because they are more likely to lead to successful medicines. Astex signed a deal this year with AstraZeneca to develop drugs for Alzheimer’s disease. The move could earn the company up to £25m. Astex was founded by two Cambridge academics, Sir Tom Blundell and Chris Abell, and by Harren Jhoti who was formerly at Glaxo Wellcome, the drug giant. The company has raised £28m from a consortium of venture-capital firms. Though Astex still has significant losses, its sales have grown 173% a year from £190,000 in 2000 to £1.4m in 2002.

This profile reflects the company at time of publication and does not reflect any changes that may have subsequently occurred. Fast Track and its sponsors do not endorse, guarantee or recommend investment in any of the companies.

Company details
Year2003
Rank12
CompanyAstex Therapeutics
ActivityDrug developer
LocationCambridge
Average 3 year sales growth172.96%
Latest sales £000s1,414
Staff85
Founded1999
Websitewww.astex-therapeutics.com

If applicable:

* supplied by company † annualised figure